Overview

A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

Status:
Completed

Trial end date:
2002-02-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to compare the effectiveness of darbopoetin alfa to placebo in the treatment of anemia in adults with lung cancer receiving multicycle platinum-containing chemotherapy, by assessing the percentage of participants who received red blood cell (RBC) transfusions during weeks 5-12 inclusive.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa